Subacute sclerosing panencephalitis (SSPE) is an uncommon type of chronic, progressive brain inflammation induced by a gradual infection with particular faulty strains of hypermutated measles virus. The disease primarily affects children, adolescents, and young adults. It is predicted that approximately 2 in 10,000 people who contract measles will develop SSPE. However, according to a 2016 study, the proportion of unvaccinated newborns under the age of 15 months could be as high as 1 in 609. There is no cure for SSPE, and the syndrome is usually always deadly. Acute disseminated encephalomyelitis, which is also caused by the measles virus but has totally different timing and duration, should not be confused with SSPE.
1. There is currently no cure for SSPE.
2. Targeted therapy of antiviral (isoprinosine and ribavirin) and immunomodulatory (interferon alpha) drugs have shown that these types of therapies, when used alone or in combination, can halt disease progression and prolong life, but their long-term effects on individuals and eventual outcome are unknown.
3. The most critical part of SSPE treatment is good nursing care, along with anticonvulsant and antispasmodic medicines as needed.
4. If the diagnosis is made during stage 1, treatment with oral isoprinosine (Inosiplex) and intraventricular interferon alfa may be possible; however, the response to these medications varies from patient to patient, and the only acknowledged treatments are supportive measures such as anticonvulsants. Once stage 2 begins, the condition is unavoidably lethal.
Behavioral changes,Involuntary muscle movements,Dementia,Neurological deterioration
Inosine pranobex,Interferon alfa,Ribavirin,Lamivudine